臺灣博碩士論文加值系統

板藍根及大黃，在臨床上以證實有許多功效，包括抗細菌、抗病毒、抗腫瘤之效果。本研究的目的在於評估板藍根及大黃之粗抽物及指標成分對於抗日本腦炎病毒功效之探討。首先利用MTT方法分析藥物濃度百分之五十的毒殺效果 ( 50% Cytotoxicity Concentration,
CC50)，以及病毒蝕斑試驗來分析板藍根、大黃及其指標成分對日本
腦炎病毒之抑制百分之五十之病毒濃度 ( 50% Inhibiting
Concentration, IC50)。板藍根乙酸乙酯粗抽物之 IC50為91.57±3.54 μg/mL，板藍根甲醇粗抽物之 IC50為78.47±3.06 μg/mL，板藍根指標成分 indigo之 IC50為37.49±3.18 μg/mL，板藍根指標成分 indirubin之 IC50為13.68±2.83 μg/mL，大黃甲醇粗抽物之 IC50為15.04±5.15 μg/mL，大黃水粗抽物之 IC50為51.41±4.95 μg/mL，大黃指標成分chrysophanol 之 IC50為15.82±2.62 μg/mL，大黃指標成分 aloe-emodin之 IC50為17.39±0.58 μg/mL。發現板藍根粗萃物、大黃萃取物及其指標成分對於三株細胞分別有不同的毒性，而在利用抑制日本腦炎病毒之 IC50來決定接下來實驗所需的藥物。以 virucidal effect 實驗來抑制日本腦炎病毒，發現板藍根乙酸乙酯、板藍根甲醇濃度 100 μg/mL、10 μg/mL、1 μg/mL抑制日本腦炎病毒分別為 54.58%、32.49%、26.35%， 62.90%、45.26%、22.42%。於濃度 10 μg/mL、1 μg/mL、0.1 μg/mL抑制日本腦炎病毒分別為61.94%、35.48%、27.81%， 78.71%、62.24%、30.65%。之後以即時定量 PCR（Real-time PCR）實驗顯示出，在細胞以藥物及病毒處理後，會造成日本腦炎病毒複製倍數下降，顯示出藥物可以抑制日本腦炎病毒動態複製情形。。另一方面以日本腦炎病毒 NS2B-NS3蛋白脢活性分析，發現 indigo 及 indirubin 有抑制日本腦炎病毒 NS2B-NS3蛋白切割能力。進一步利用流式細胞儀來測試細胞 NO 產生， 結果顯示板藍根、大黃及其指標成分皆會導致 NO 量的增加。進一步利用 Fluorescent ISRE-SEAP 報導基因分析證實板藍根及指標成分會促使細胞產生干擾素之抗病毒作用。

Isatis indigotica and Rheum palmatum have been demonstrated to have various clincal activities, including antibacterial, antiviral and anti-tumor effects. The goal of this study is to investigate the antiviral effects of
Isatis indigotica, Rheum palmatum and their marker compounds against Japanese encephalitis virus ( JEV) in vitro cell culture assay. First, MTT assay was used measured for 50% cytotoxicity concentration (CC50) of
each extract and marker compounds. The plaque assay was carried out fore detecting 50% inhibiting concentration ( IC50) of Isatis indigotica, Rheum palmatum and their marker compounds to against JEV. The IC50 values of the ethyl acetate and methanol extract of Isatis indigotica against JEV were 91.57±3.54 μg/mL and 78.47±3.06 μg/mL , respectively. The IC50 values of the indigo and indirubin against JEV were 37.49±3.18 μg/mL and 13.68±2.83 μg/mL, respectively. Methanol and water extracts of Rheum palmatum against JEV were the IC50 of 15.04±5.15 μg/mL and the IC50 of 51.41±4.95 μg/mL , respectively. Chrysophanol and aloe-emodin against JEV was the IC50 of 15.82±2.62 μg/mL and the IC50 of 17.39±0.58 μg/mL, respectively. Testing for
virucidal effect of ethyl acetate extract of Isatis indigotica ( 100 μg/mL , 10 μg/mL , 1 μg/mL ) inhibit on JEV was 54.58%、32.49%、26.35%, methanol of extract of Isatis indigotica ( 100 μg/mL , 10 μg/mL , 1 μg/mL ) inhibit on JEV was 62.90%、45.26%、22.42%. Indigo and
indirubin( 10 μg/mL、1 μg/mL、0.1 μg/mL ) inhibit on JEV was 1 61.94%、35.48%、27.81% and 78.71%、62.24%、30.65%, respectively.Isatis indigotica and Rheum palmatum have been demonstrated to have various clincal activities, including antibacterial, antiviral and anti-tumor effects. The goal of this study is to investigate the antiviral effects of
Isatis indigotica, Rheum palmatum and their marker compounds against Japanese encephalitis virus ( JEV) in vitro cell culture assay. First, MTT assay was used measured for 50% cytotoxicity concentration (CC50) of
each extract and marker compounds. The plaque assay was carried out fore detecting 50% inhibiting concentration ( IC50) of Isatis indigotica, Rheum palmatum and their marker compounds to against JEV. The IC50 values of the ethyl acetate and methanol extract of Isatis indigotica against JEV were 91.57±3.54 μg/mL and 78.47±3.06 μg/mL ,
respectively. The IC50 values of the indigo and indirubin against JEV were 37.49±3.18 μg/mL and 13.68±2.83 μg/mL, respectively. Methanol and water extracts of Rheum palmatum against JEV were the IC50 of 15.04±5.15 μg/mL and the IC50 of 51.41±4.95 μg/mL , respectively. Chrysophanol and aloe-emodin against JEV was the IC50 of 15.82±2.62 μg/mL and the IC50 of 17.39±0.58 μg/mL, respectively. Testing for
virucidal effect of ethyl acetate extract of Isatis indigotica ( 100 μg/mL , 10 μg/mL , 1 μg/mL ) inhibit on JEV was 54.58%、32.49%、26.35%, methanol of extract of Isatis indigotica ( 100 μg/mL , 10 μg/mL , 1
μg/mL ) inhibit on JEV was 62.90%、45.26%、22.42%. Indigo and indirubin( 10 μg/mL、1 μg/mL、0.1 μg/mL ) inhibit on JEV was 1 61.94%、35.48%、27.81% and 78.71%、62.24%、30.65%, respectively.Moreover, real-time PCR demonstrated the inhibition of JEV titers by Isatis indigotica, Rheum palmatum and their marker compounds.Otherwise, Isatis indigotica and its marker compounds inhibited the
proteolytic activity of the JEV NS2B-NS3 protease.
Furthermore, flow cytometry assay showed that Isatis indigotica, Rheum palmatum and their marker compounds stimulated the NO production in human promonocyte cells.
Moreover, interferon stimulated response element- SEAP (ISRE-SEAP) cis-acting reporter assay indicated that Isatis indigotica and its marker compounds induced the cis-acting reporter activity, being responsible for the interferon-mediated antiviral ability.

目 錄
中文摘要 iii
英文摘要 v
圖附錄 vii
表附錄 xi
略字表 xii
第一章 緒論 1
第一節 計畫緣起 1
第二節 研究目的 3
第三節 論文構架 4
第二章 文獻回顧 5
第一節 板藍根文獻回顧 5
第二節 大黃文獻回顧 11
第三節 日本腦炎病毒 ( Japanese encephalitis virus, JEV) 18
第四節 抗病毒作用機轉 22
第三章 研究內容與研究方法 25
第一節 實驗材料 25
第二節 實驗方法 28
第四章 研究結果 41
第一節 板藍根研究結果 41
第二節 大黃研究結果 48
第五章 討論 55
第六章 結論與建議 58
第七章 參考文獻 59
附圖 69
附表 111
附錄 120

1.George B Lenon, Charlie CL Xue, David F Story, Frank CK Thien, Sarah McPhee and Chun G Li. Inhibition of release of inflammatory mediators in primary and cultured cells by a Chinese herbal medicine formula for allergic rhinitis. Chinese Medicine, 2007, 1-8.
2.Yibing Xu, Bryant G. Oliverson, Daniel L. Simmons. Trifunctional inhibition of COX-2 by extracts of Lonicera japonica: Direct inhibition, transcriptional and post-transcriptional down regulation. Journal of Ethnopharmacology, 2007, 111 , 667–670.
3.Ming-Jen Hsu, Shiuh-Sheng Lee, Sho Tone Lee, Wan-Wan Lin. Signaling mechanisms of enhanced neutrophil phagocytosis and chemotaxis by the polysaccharide purified from Ganoderma lucidum. British Journal of Pharmacology, 2003, 139, 289–298.
4.Qinglong Guoa, Li Zhao, Qidong You, Yong Yang , Hongyan Gu, Guoliang Song, Na Lu, Jian Xin. Anti-hepatitis B virus activity of wogonin in vitro and in vivo. Antiviral Research, 2007, 74, 16–24.
5.Hui-Liang Li, Wei-Dong Zhang, Chuan Zhang, Run-Hui Liu, Xiang-Wei Wang, Xiao-Lin Wang, Jian-Bao Zhu and Chun-Lin Chen. Bioavailabilty and pharmacokinetics of four active alkaloids of traditional Chinese medicine Yanhuanglian in rats following intravenous and oral administration. Journal of Pharmaceutical and Biomedical Analysis, 2006, 41, 1342–1346.
6.Xiaoyan Wang, Wei Jia, Aihua Zhao and Xiaorong Wang. Anti-influenza Agents from Plants and Traditional Chinese Medicine. Phytother. Res, 2006, 20, 335–341.
7.Jin-Peng Guo, Ji Pang, Xin-Wei Wang, Zhi-Qiang Shen, Min Jin, Jun-Wen Li .In vitro screening of traditionally used medicinal plants in China against Enteroviruses. World J Gastroenterol, 2006, 12(25): 4078-4081.
8.Xiao-Yin Chen, Guang-Dong Tong, Fang Xia.Antiviral effect of Chinese medicine jiaweisinisan in hepatitis B virus transgenic mice. World J Gastroenterol 2006, 12(14), 2280-2283.
9.Miaomiao Xi, Chunxu Hai, Haifeng Tang, Mingsheng Chen, Kunquan Fang and
Xin Liang. Antioxidant and antiglycation properties of total saponins extracted from traditional Chinese medicine used to treat diabetes mellitus. Phytother. Res., 2007, 1-10.
10.Chen Feng, Hengxiao Wang, Chengfang Yao, Jian Zhang, Zhigang Tian. Diammonium glycyrrhizinate, a component of traditional Chinese medicine Gan-Cao, prevents murine T-cell-mediated fulminant hepatitis in IL-10- and IL-6-dependent manners. International Immunopharmacology, 2007, 7, 1292–1298.
11.Mingyu Sun, Jun Han, Jifeng Duan, Yumin Cui, Tao Wang, Weihan Zhang, Wei Liu, Jianrong Hong, Minghui Yao, Sidong Xiong and Xiaoqiang Yan. Novel Antitumor Activities of Kushen Flavonoids In Vitro and In Vivo. Phytother. Res. , 2007, 21, 269–277.
12.Xinning Wang, Steve C.F. Au-Yeung, Yee-Ping Ho .Pharmacokinetics and tissue distribution of novel traditional Chinese medicine-platinum anticancer agents in rats. Journal of Inorganic Biochemistry, 2007, 101, 909–917.
13.Ma, Yan-Xia; Fu, Hong-Zheng; Li, Min; Sun, Wan; Xu, Bo; Cui, Jing-Rong. An anticancer effect of a new saponin component from Gymnocladus chinensis Baillon through inactivation of nuclear factor-[kappa]B. Anti-Cancer Drugs. , 2007, 18(1), 41-46.
14.Ya-Ling HSU, Ming-Hong YEN, Po-Lin KUO, Chien-Yu CHO, Yu-Ting HUANG, Chien-Jung TSENG, Ju-Ping LEE, Chun-Ching LIN. Inhibits the Proliferation of Human Breast Cancer Cell by Blocking Cell Cycle Progression and Inducing Apoptosis. Biol. Pharm. Bull. , 2006, 29(12), 2388-2394.
15.Thomas M. Ehrman, David J. Barlow, Peter J. Hylands. Virtual Screening of Chinese Herbs with Random Forest. J. Chem. Inf. Model. 2007, 47, 264-278.
16.P.M.K. Poon, C.K. Wong, K.P. Fung, C.Y.S. Fong, E.L.Y. Wong, J.T.F. Lau, P.C. Leung, S.K.W Tsui, D.C.C. Wan, M.M.Y. Waye, S.W.N. Au, C.B.S. Lau, C.W.K. Lam. Immunomodulatory Effects of a Traditional Chinese Medicine with Potential Antiviral Activity: A Self-Control Study. The American Journal of Chinese Medicine, 2007, 34(1), 13–21.
17.Ko HC, Wei BL, Chiou WF. The effect of medicinal plants used in Chinese folk medicine on RANTES secretion by virus-infected human epithelial cells. J Ethnopharmacol. 2006 , 107(2), 205-10.
18.Xu T, Tang K, Zhang H, Guo M, Zhang L, Li F. Transformation of bar gene to tetraploid of Isatis indigotica. Zhong Yao Cai. 2003, 26(5) , 313-5.
19.Wei-Jun Kong, Yan-Ling Zhao, Li-Mei Shan, Xiao-He Xiao and Wei-Ying Guo, Correlation analysis between the HPLC fingerprints and in vitro antibacterial activity of ethyl acetate extracts from Radix isatidis, Journal of Chinese Pharmaceutical Sciences, 2007, 16, 282–287.
20.Wu XY, Qin GW, Cheung KK, Cheng KF. New alkaloids from Isatis indigotica. Tetrahedron, 1997, 53 (39), 13323–13328
21.Yu-Ling Ho, Yuan-Shiun Chang, Studies on the antinociceptive, anti-inflammatory and antipyretic effects of Isatis indigotica root, Phytomedicine, 2002, 9, 419–424.
22.Danz H, Stoyanova S, Thomet OA, Simon HU, Dannhardt G, Ulbrich H, Hamburger M. Inhibitory activity of tryptanthrin on prostaglandin and leukotriene synthesis. Planta Med. 2002 , 68(10) , 875-80.
23.何玉鈴.2001.板藍根、大青葉及青黛之生藥學及藥理學研究.中國醫藥學院博士論文.
24.何玉鈴、郭昭麟、高國清、陳忠川、張永勳.2001.板藍根藥材之鑑別研究.中國醫藥學院雜誌12:267-283.
25.清華,中草藥, 1983, 14, 8-9.
26.劉思貞、祝希嫻、邵玉芹、馬天波.板藍根抗流感病毒有效部位的篩選.中草藥1999, 9, 24-26.
27.Nai-Ki Mak, Chung-Yee Leung, Xiao-Yi Wei, Xiao-Ling Shen, Ricky Ngok-Shun Wong, Kwok-Nam Leung, Ming-Chiu Fung. Inhibition of RANTES expression by indirubin in influenza virus-infected human bronchial epithelial cells, Biochemical Pharmacology, 2004, 67, 167–174.
28.沈忠良等,生大黃防治肝炎肝硬化上消化道出血後併發症23例,浙江中西醫結合雜誌, 2001, 12(11), 773-774.
29.邱崇怡等,中西醫結合治療應激性潰瘍大出血40例,湖南中醫雜誌, 2002, 1(18), 34-35.
30.尹立剛等,金黃散治療外傷性腫痛1400例,湖南中醫雜誌, 1(16), 40-41.
31.台慧玲等,中西醫結合治療淤膽型肝炎臨床觀察,北京中醫,2000, 5(19), 18-16.
32.黃曉敏等,大黃體外抗無芽胞厭氧菌的體外實驗研究,中醫藥信
息, 2001, 1(8), 41-42.
33.Lu M, Chen QH, Studies of Chinese rhubarbXII. Effect of anthraquinone
derivatives on the respiration and glycolysis of Ehrlich ascites carcinoma cells. Acta Pharm Sin 1980. 15, 65-70.
34.Lu M, Chen QH, Biochemical study of Chinese rhubarb XXIX. Inhibitory effects of anthraquinone derivatives on P338 leukaemia in mice. J China Pharm Univ 1989, 20, 155-157.
35.Chang CJ, Ashendel CL. Chan TC, Geahlen RL, McLaughlin J, Waters DJ,Oncogene signal transduction inhibitors from Chinese medicinal plants. Pure Appl. Chem 1999, 71, 1101-1104.
36.Fuzellier MC, Mortier F, Girard T, Payen J. Study of antibiotic properties of some anthraquinones using chromatographic microplates. Ann Pharm Fr 1981, 39, 313-318.
37.Cyong JC, et. al Anti-Bacteriodes fragilis substance from rhubarb. J Ethnopharmacol 1987, 19, 279-283.
38.Lu M, Chen QH, Studies of Chinese rhubarbXII. Effect of anthraquinone derivatives on the respiration and glycolysis of Ehrlich ascites carcinoma cells.Acta Pharm Sin 1980, 15, 65-70.
39.Lu M, Chen QH, Biochemical study of Chinese rhubarb XXIX. Inhibitory effects of anthraquinone derivatives on P338 leukaemia in mice. J China Pharm Univ1989, 20, 155-157.
40.Chang CJ, Ashendel CL. Chan TC, Geahlen RL, McLaughlin J, Waters DJ, Oncogene signal transduction inhibitors from Chinese medicinal plants. Pure Appl. Chem 1999, 71, 1101-1104.
41.Zhang JH, Zhang M, Clinical effects of rheum and captopril on preventing progression of chronic renal failure. Chin Med J 1990, 103, 788-93.
42.Zhi Li, Li-jun Li, Yan Sun, Jing Li, Identification of natural compounds with anti-hepatitis B virus activity from Rheum palmatum L. ethanol extract. Chemotherapy , 2007, 53(5), 320-6.
43.I. Ltto, Z. Q. Yang. H. Xiao, Y.W. Liu, Rheum palmatum therapy for herpes simplex virus infection in mice. Antiviral Research, 1996, 30(1), pp. 45-45.
44.Sydiskis RJ, Owen DG, Lohr JL, Rosler KH, Blomster RN. Inactivation of enveloped viruses by anthraquinones extracted from plants. Antimicrobial Agents & Chemotherapy, 1991, 35, 2463-6.
45.May G, Willuhn G. Antiviral activity of aqueous extracts from medicinal plants in tissue cultures. Arzneim-Forsch, 1978, 28, 1-7.
46.Kurokawa M, Ochiai H, Nagasaka K. Antiviral traditional medicines against Herpes simplex virus (HSV1), poliovirus, and measles virus in vitro. Antiviral Res 1993, 22, 175-88.
47.The Merck Index 13th
48.Talal A. Aburjai. Anti-platelet stilbenes from aerial parts of Rheum palaestinum, Phytochemistry, 2000, 55, 407-410.
49.胡凱文,侯麗,陳信義,孫穎立,大黃酸/大黃素抗多耐藥腫瘤細胞研究,中國中醫基礎醫學雜誌, 1998, 4(11), 19-20.
50.S.O. Mueller, M. Schmitt, W. Dekant, H. Stopper, J. Schreier, P. Schreier, W. Klutz. Occurrence of Emodin, Chrysophanol and Physcion in Vegetables, Herbs and Liquors. Genotoxicity and Anti-genotoxicity of the Antraquinones and of the Whole Plants. Food and Chemical Toxicology, 1999, 37, 481-491.
51.Mengs U, Krumbiegel G, Volkner W. Lack of emodin genotoxicity in the mouse micronucleus assy. Mutation Research. 1997, 393(3), 289-93.
52.Solomon T, Dung NM, Kneen R, Gainsborough M, Vaughn DW, Khanh VT. Japanese encephalitis. J Neurol Neurosurg Psychiatry, 2000, 68(4), 405-415.
53.Mirmomeni MH, Hughes PJ, Stanway G. An RNA tertiary structure in the 3'' untranslated region of enteroviruses is necessary for efficient replication. J Virol. 1997, 71(3), 2363-2370.
54.行政院衛生署疾病管制局
55.Cheng-Wen Lin,Kuan-HsunLin,Ping-Chiang Lyu.Wei-June Chend.Japanese encephalitis virus NS2B-NS3 protease binding to phage-displayed human brain proteins with the domain of trypsin inhibitor and basic region leucine zipper. Virus Research, 2006, 116, 106–113.
56.Chun-Tang Chiou, Chih-Chi Andrew Hu , Pi-Hsin Chen, Ching-Len Liao, Yi-Ling Lin and Jaang-Jiun Wang .Association of Japanese encephalitis virus NS3 protein with microtubules and tumour susceptibility gene 101 (TSG101) protein. J.Ge.nVirol, 2003, 84, 2795-2805.
57.Lindenbach,B.D,andRice,C.M..Flaviridae：the virus and their replication. InFields Virology, 4 , 991-1041.
58.Satchidanandam V, Uchil PD, Kumar P. Organization of flaviviral replicase proteins in virus-induced membranes: a role for NS1'' in Japanese encephalitis virus RNA synthesis. Novartis Found Symp.277,136-45 discussion, 2006, 145-8, 251-3.
59.Xueqin Liu, Shengbo Cao1 , Rui Zhou, Gaoyuan Xu, Shaobo Xiao, Ying Yang, Minxuan Sun, Yaoming Liand Huanchun Chen. Inhibition of Japanese encephalitis virus NS1 protein expression in cell by small interfering RNAs. Virus Genes, 2006, 33, 69-75.
60.Uchil PD, Kumar AV, Satchidanandam V. Nuclear localization of flavivirus RNA synthesis in infected cells. J Virol, 2006, 80(11), 5451-64.
61.Lin CW, Huang HD, Shiu SY, Chen WJ, Tsai MH, Huang SH, Wan L, Lin YJ. Functional determinants of NS2B for activation of Japanese encephalitis virus NS3 protease.Virus Res. 2007, 127(1), 88-94.
62.Takegami T, Sakamuro D, Furukawa T. Japanese encephalitis virus nonstructural protein NS3 has RNA binding and ATPase activities. Virus Genes. 1995, 9(2), 105-120.
63.Dong-Kun Yang, Chang-Hee Kweon, Byoung-Han Kim, In-Jin Hwang, Mun-I Kang,Byung-Jae So,Kyoung-Oh Cho. J. Vet. Sci. 2007, 8(2), 197–199.
64.McMinn,P.C.The molecular basis of virulence of the encephalitogenic flaviviruses.J.Gen.Virol. 1997, 78, 2711-2722.
65.Suchetana M , Richard J. Kuhn , Michael G. Rossmann. A structural perspective of the flavivirus life cycle. Nature reviews, MICROBIOLOGY. 2005, 3, 13-22.
66.Sarah D. Cady and Mei Hong, Amantadine-induced conformational and dynamical changes of the influenza M2 transmembrane proton channel. PNAS, 2008, 105(5), 1483–1488.
67.Anice C. Lowen, Peter Palese. Influenza Virus Transmission: Basic Science and Implications for the Use of Antiviral Drugs During a Pandemic. Infectious Disorders - Drug Targets 2007, 7, 318-328.
68.De Clercq E, Field HJ. Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol. 2006 , 147(1), 1-11.
69.Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol. 2008 Jul, 8(7), 559-68.
70.Pan L, Huang YW, Ye YR, Wang YQ. A model for screening anti-viral agents based on yeast killer system. Wei Sheng Wu Xue Bao. 2007 Jun 4;47(3):517-21.
71.Kang HS, Lee JY, Kim CJ. Anti-inflammatory activity of arctigenin from Forsythiae Fructus. J Ethnopharmacol. 2008 Mar 5;116(2):305-12. Epub 2007 Nov 26.
72.Kawata J, Kameda M, Miyazawa M. Cyclooxygenase-2 inhibitory effects and composition of the volatile oil from the dried roots of Lithospermum erythrorhizon. Nat Med (Tokyo). 2008, 62(2), 239-43.
73.Li S, Wang R, Zhang Y, Zhang X, Layon AJ, Li Y, Chen M.Symptom combinations associated with outcome and therapeutic effects in a cohort of cases with SARS. Am J Chin Med. 2006, 34(6), 937-47.
74.Li SS, Li HY, Piao YA, Liu DL, Tian WJ, Dong YM.The anti-respiratory syncytial virus effect of an active compound (AP3) from a Chinese medicinal herb-Herba patriniae in vitro. Zhonghua Liu Xing Bing Xue Za Zhi. 2004 , 25(2), 150-3.
75.Bodinet C, Mentel R, Wegner U, Lindequist U, Teuscher E, Freudenstein J. Effect of oral application of an immunomodulating plant extract on Influenza virus type A infection in mice. Planta Med. 2002 , 68(10), 896-900.
76.Ai P, Yong G, Dingkun G, Qiuyu Z, Kaiyuan Z, Shanyan L. Aqueous extract of Astragali Radix induces human natriuresis through enhancement of renal response to atrial natriuretic peptide. J Ethnopharmacol. 2008 , 116(3), 413-21.
77.Zhang ZC, Li SJ, Yang YZ, Chen RZ, Ge JB, Chen HZ. Effect of astragaloside on cardiomyocyte apoptosis in murine coxsackievirus B3 myocarditis. Journal of Asian Natural Products Research, 2007, 9(2), 145 – 151.
78.Fei Chen, Yongju Lu, Vince Castranova, Yon Rojanasakul, Kaoru Miyahara, Yutaka Shizuta, Val Vallyathan, Xianglin Shi, Laurence M. Demers, Nitric Oxide Inhibits HIV Tat-Induced NF-KκB Activation, American Journal of Pathology,1999, 155(1), 275-84..
79.Spiecker M, Peng HB, Liao JK: Inhibition of endothelial vascular cell adhesion molecule-1 expression by nitric oxide involves the induction and nuclear translocation of IkBa. J Biol Chem , 1997, 272, 30969–30974.
80.Taylor BS, Kim YM, Wang Q, Shapiro RA, Billiar TR, Geller DA: Nitric oxide down-regulates hepatocyte-inducible nitric oxide synthase gene expression. Arch Surg, 1997, 132, 1177–1183.
81.Togashi H, Sasaki M, Frohman E, Taira E, Ratan RR, Dawson TM, Dawson VL: Neuronal (type I) nitric oxide synthase regulates nuclear factor kappa B activity and immunologic (type II) nitric oxide synthase expression. Proc Natl Acad Sci USA 1997, 9, 2676–2680.
82.Park SK, Lin HL, Murphy S: Nitric oxide regulates nitric oxide synthase- 2 gene expression by inhibiting NF-kB binding to DNA. Biochem J 1997, 322, 609–613.
83.Khan BV, Harrison DG, Olbrych MT, Alexander RW, Medford RM: Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci USA 1996, 93, 9114–9119.
84.Matthews JR, Botting CH, Panico M, Morris HR, Hay RT: Inhibition of NF-kB DNA binding by nitric oxide. Nucleic Acids Res 1996, 24, 2236–2242.
85.Hibbs Jr., J.B., Taintor, R.R., Vavrin, Z., Rachlin, E.M., 1998. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem. Biophys. Res. Commun, 1988, 157(1), 87–94.
86.Martin Ivec , Tanja Boti´c , Sreˇcko Koren , Mogens Jakobsen ,Hana Weingartl , Avrelija Cenciˇc , Interactions of macrophages with probiotic bacteria lead to increased antiviral response against vesicular stomatitis virus. M. Ivec et al. Antiviral Research, 2007, 75, 266–274.